(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.
Quoin Pharmaceuticals's earnings in 2026 is -$16,990,211.On average, 6 Wall Street analysts forecast QNRX's earnings for 2026 to be -$464,619,287, with the lowest QNRX earnings forecast at -$544,909,797, and the highest QNRX earnings forecast at -$352,808,673. On average, 5 Wall Street analysts forecast QNRX's earnings for 2027 to be -$235,894,669, with the lowest QNRX earnings forecast at -$330,665,869, and the highest QNRX earnings forecast at -$141,713,944.
In 2028, QNRX is forecast to generate -$114,242,808 in earnings, with the lowest earnings forecast at -$219,755,025 and the highest earnings forecast at $47,976,075.